A Phase 1 interventional study of LY3502970 and Clarithromycin in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with clarithromycin in healthy participants. This study will last up to approximately 85 days for each participant.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single 3 milligram (mg) dose of LY3502970 administered orally on Day 1. Participants were fasted overnight and remained in a fasted state for 4 hours after taking the study drug.
Drug: LY3502970
Participants received below: Day 15 to 31: 500 mg of clarithromycin administered orally every 12 hours (Q12H). Day 21: 500 mg clarithromycin followed by 3 mg LY3502970 administered orally. Participants fasted overnight and remained in a fasted state for 4 hours after taking the study drug. Clarithromycin was administered 1 hour prior to LY3502970 dose administration, and a subsequent clarithromycin dose was administered 12 hours later
Drug: LY3502970 · Drug: Clarithromycin
Administered orally.
Administered orally.
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Infinity AUC(0-∞) of LY3502970
PK: AUC(0-∞) of LY3502970 is reported.
Time frame: Period 1: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours Day 1 postdose; Period 2: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 168 and 240 hours Day 21 postdose
PK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of LY3502970
PK: AUC(0-tlast) of LY3502970 is reported.
Time frame: Period 1: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours Day 1 postdose; Period 2: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 168 and 240 hours Day 21 postdose
PK: Maximum Observed Concentration (Cmax) of LY3502970
PK: Cmax of LY3502970 is reported.
Time frame: Period 1: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours Day 1 postdose; Period 2: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 168 and 240 hours Day 21 postdose
| Milestone | 3 mg LY3502970 (Day 1) and 500 mg Clarithromycin Q12H + 3 mg LY3502970 (Day 21) |
|---|---|
| Started | 26 |
| Received at least one dose of study drug | 26 |
| Completed | 21 |
| Not completed | 5 |
| Withdrew: Adverse event | 5 |
| Milestone | 3 mg LY3502970 (Day 1) and 500 mg Clarithromycin Q12H + 3 mg LY3502970 (Day 21) |
|---|---|
| Started | 21 |
| Received at least one dose of study drug | 21 |
| Completed | 21 |
| Not completed | 0 |
PK: AUC(0-∞) of LY3502970 is reported.
| nanogram*hour per milliliter (ng*hr/mL) | LY3502970 (Day 1) | Clarithromycin + LY3502970 (Day 21) |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Infinity AUC(0-∞) of LY3502970 | 380 ± 40 | 1380 ± 31 |
PK: AUC(0-tlast) of LY3502970 is reported.
| ng*h/ mL | LY3502970 (Day 1) | Clarithromycin + LY3502970 (Day 21) |
|---|---|---|
| PK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of LY3502970 | 333 ± 37 | 1270 ± 30 |
PK: Cmax of LY3502970 is reported.
| nanograms per milliliter (ng/mL) | LY3502970 (Day 1) | Clarithromycin + LY3502970 (Day 21) |
|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of LY3502970 | 15.4 ± 38 | 30.4 ± 30 |
Collected over Baseline up to 43 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3 mg LY3502970 | 0/26 (0%) | 0/26 (0%) | 23/26 (88.5%) |
| 500 mg Clarithromycin Q12H | 0/21 (0%) | 0/21 (0%) | 9/21 (42.9%) |
| 500 mg Clarithromycin Q12H + 3 mg LY3502970 | 0/21 (0%) | 0/21 (0%) | 21/21 (100%) |
| Event | 3 mg LY3502970 | 500 mg Clarithromycin Q12H | 500 mg Clarithromycin Q12H + 3 mg LY3502970 |
|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 13/26 | 0/21 | 10/21 |
| VomitingGastrointestinal disorders | 11/26 | 0/21 | 10/21 |
| NauseaGastrointestinal disorders | 9/26 | 0/21 | 7/21 |
| HeadacheNervous system disorders | 9/26 | 0/21 | 6/21 |
| DizzinessNervous system disorders | 3/26 | 0/21 | 7/21 |
| Abdominal distensionGastrointestinal disorders | 8/26 | 0/21 | 5/21 |
| Catheter site erythemaGeneral disorders | 0/26 | 0/21 | 6/21 |
| Catheter site bruiseGeneral disorders | 2/26 | 0/21 | 4/21 |
| Catheter site painGeneral disorders | 0/26 | 0/21 | 4/21 |
| DiarrhoeaGastrointestinal disorders | 1/26 | 2/21 | 3/21 |
All participants who received at least one dose of the study drug.
| Age, Continuous(years) | Overall Participants |
|---|---|
| Mean | 44.9 ± 11.8 |
| Sex: Female, Male(Participants) | Overall Participants |
|---|---|
| Female | 3 |
| Male | 23 |
| Ethnicity (NIH/OMB)(Participants) | Overall Participants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 26 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 26 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Overall Participants |
|---|---|
| Singapore | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Nov 2022, 3 months.
Results were first posted in May 2026, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron